Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BtuF is a periplasmic binding protein in Gram-negative bacteria, such as Escherichia coli, that plays a critical role in the high-affinity uptake of Vitamin B12 (cobalamin) [1, 4]. It is a key component of the BtuCDF ABC transporter system, where it captures B12 in the periplasmic space and delivers it to the BtuCD membrane complex for ATP-dependent transport into the cytoplasm [2, 9]. Structurally, BtuF consists of two lobes that close around the B12 molecule, a process often described by the Venus flytrap mechanism [7, 8]. Because Vitamin B12 is an essential cofactor for various bacterial metabolic pathways, BtuF is considered a promising target for the development of narrow-spectrum antibacterial agents that aim to starve pathogens of vital nutrients [11, 21]. While no clinical drugs currently target BtuF, research into small-molecule inhibitors and nanobodies is ongoing to combat antibiotic-resistant infections [21, 27].
Competitive inhibition of Vitamin B12 binding or steric blocking of the interaction between the BtuF protein and the BtuCD transmembrane transporter complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitamin B12-binding protein (BtuF) (BtuF).